查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863423

血液和血漿成分市場按產品類型、應用、最終用戶和分銷管道分類－2025年至2032年全球預測

Blood & Plasma Components Market by Product Type, Application, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，血液和血漿成分市場將成長至 725.5 億美元，複合年成長率為 5.90%。

關鍵市場統計數據
基準年 2024 458.6億美元
預計年份：2025年 486.2億美元
預測年份 2032 725.5億美元
複合年成長率 (%) 5.90%

本次培訓重點在於影響醫療系統和產業領導者血液和血漿成分管理的臨床、營運和商業性動態。

血液和血漿成分在現代醫療保健服務中發揮核心作用，為治療通訊協定、診斷流程和生物醫學研究提供支援。本導論概述了影響供應鏈和相關人員決策的核心臨床和商業性因素。它整合了成分加工的最新進展、不斷變化的法規環境以及不斷變化的臨床需求模式，為讀者理解後續的分析章節奠定了基礎。

臨床醫生和採購負責人面臨臨床需求與供應鏈限制之間錯綜複雜的相互作用。一方面，在多種適應症中，對血漿蛋白（例如免疫球蛋白和凝血因子）的治療依賴性仍然很高。另一方面，從捐贈者招募和採集物流到低溫運輸管理和分銷管道轉型，營運壓力要求各機構採取全面應對措施。本導言透過闡明關鍵的變革促進因素，幫助領導者評估風險、優先考慮應對措施，並將投資與臨床需求保持一致。

本節最後闡明了貫穿整個報告的分析方法：重點關注產品特定趨勢、應用主導的使用模式、終端用戶操作實踐以及通路效能。這種想法清晰地引導讀者理解後續的深入分析，使他們能夠將洞見轉化為戰術性和策略行動，從而改善患者照護並提升組織韌性。

技術創新、不斷變化的監管環境以及供應鏈多元化正在共同重塑血液和血漿生態系統的需求結構和韌性策略。

該產業正經歷變革性的轉變，相關人員管理供應、品質和商業策略的方式也隨之改變。血漿分餾和病原體去除技術的進步提高了產品的安全性和保存期限，而皮下注射劑型和重組替代療法的創新則改變了治療使用模式。同時，捐血互動和庫存管理的數位化正在最佳化血液採集處理能力，減少廢棄物，並建立更靈活的供應網路。這些技術主導的改進與臨床實踐的轉變相輔相成，精準醫療和標靶治療正在影響各個產品類型的需求結構。

政策法規的演變也在推動改變。監管機構正在實施更嚴格的藥物監測要求，並針對血漿衍生產品製定新的指導方針，要求製造商和經銷商在整個生命週期中加強監管。此外，地緣政治緊張局勢和貿易政策調整更強調區域自主和採購多元化，迫使企業和醫療系統重新評估對單一供應商的依賴。因此，商業模式正在轉向戰略夥伴關係、擴大國內生產能力以及能夠應對突發政策變化的靈活分銷協議。

這些變化共同創造了一種環境，在這種環境中，敏捷性、技術應用和監管前瞻性是關鍵的差異化因素。那些投資於整合供應鏈視覺性、採用更安全、更有效率的加工技術並積極參與不斷變化的法規結構的組織，將更有能力在滿足臨床需求的同時，維持成本效益和品質標準。

評估近期關稅調整和貿易政策變化如何重塑血液和血漿成分籌資策略、區域生產決策和供應韌性。

近期關稅和貿易政策的變化為血液和血漿成分的採購和分銷策略帶來了新的複雜性。影響進口原料、特殊試劑和成品血漿衍生產品的關稅調整，加劇了供應商和醫療系統的成本壓力，迫使採購團隊重新評估採購區域和供應商合約。為此，許多機構正優先考慮供應鏈透明度和情境規劃，以降低跨境成本波動帶來的風險。

除了直接的成本影響外，關稅變化也在影響製造商和經銷商的策略行為。一些生產商正在加速生產區域化，並建立額外的加工中心，以避免與關稅相關的摩擦，並維持進入關鍵市場的管道。作為應對，經銷商正在使其庫存多元化，並與醫療系統重新談判合約條款，以共用風險並確保醫療服務的連續性。這些調整通常涉及長期商業性承諾和對本地低溫運輸基礎設施的投資，雖然可以穩定供應，但也增加了資本密集度。

臨床醫生和醫院營運團隊正在感受到採購週期和庫存管理政策的後續影響。由於相關人員將潛在的關稅波動納入庫存和替代決策，計劃週期有所延長，因此採購、臨床和監管團隊之間的協作對於維持治療路徑至關重要。最終，不斷變化的關稅環境凸顯了製定多層次韌性策略的必要性，該策略結合了本地能力建設、靈活的分銷模式和積極的監管應對措施，以保障患者獲得治療和臨床連續性。

為市場參與企業提供基於深度細分的清晰訊息，將產品分類、臨床應用、終端用戶行為和分銷管道與營運重點和商業性策略聯繫起來。

細分市場分析揭示了產品、應用、終端用戶和分銷管道等各個維度上的微妙動態，每個維度都具有獨特的營運和商業意義。根據產品類型，市場可細分為血漿蛋白、血小板、紅血球和白血球。血漿蛋白本身需要更深入的分析。白蛋白在輸液管理和加護治療中發揮核心作用。由於凝血因子具有特定的治療用途和生產方面的考慮，因此需要對凝血因子IX、凝血因子VIII和凝血酶原複合物濃縮物進行交叉分析。免疫球蛋白也可分為靜脈注射和皮下注射兩種給藥方式，每種方式都有其獨特的給藥方法和供應需求。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 人類血漿供應緊張導致對重組白蛋白替代品的需求增加。
  • 透過開發高免疫球蛋白療法來增強對新興感染疾病的被動免疫力
  • 擴大亞太地區的分餾產能，以滿足日益成長的免疫球蛋白治療需求
  • 在血液處理中採用病原體減少技術以提高輸血安全標準
  • 為了提高捐血數量和效率，對連續血漿置換機的投資增加。
  • 血漿分餾生產商之間的整合日益加劇，正在重塑競爭格局和定價策略。
  • 轉向分散式血庫模式，並採用即時檢測技術，以擴大遍遠地區的血液供應。
  • 將人工智慧應用於預測捐血篩檢和最佳化供應鏈
  • 重組凝血因子的出現減少了對血漿衍生濃縮物的依賴。
  • 引進一種新型病毒去活化方法，以解決血漿製品的安全問題。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按產品類型分類的血液和血漿成分市場

  • 血漿蛋白
    • 白蛋白
    • 凝血因子
      • 因子九
      • 因子 VIII
      • 凝血酶原複合物濃縮物
    • 免疫球蛋白
      • 靜脈注射免疫球蛋白
      • 皮下注射免疫球蛋白
  • 血小板
  • 紅血球
  • 白血球

9. 按應用分類的血液和血漿成分市場

  • 診斷
  • 研究
  • 治療用途

第10章 按最終用戶分類的血液和血漿成分市場

  • 診斷實驗室
  • 醫院
    • 門診手術中心
    • 公立醫院
    • 私立醫院
  • 研究所

11. 按分銷管道分類的血液和血漿成分市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

12. 按地區分類的血液和血漿成分市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

13. 按組別分類的血液和血漿成分市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國血液和血漿成分市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • CSL Limited
    • Grifols, SA
    • Takeda Pharmaceutical Company Limited
    • Octapharma AG
    • Biotest AG
    • KEDRION SpA
    • Shanghai RAAS Blood Products Co., Ltd
    • Bio Products Laboratory Limited
    • LFB SA
    • Sanquin Blood Supply Foundation
Product Code: MRR-5C6F41F5AF8E

The Blood & Plasma Components Market is projected to grow by USD 72.55 billion at a CAGR of 5.90% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 45.86 billion
Estimated Year [2025] USD 48.62 billion
Forecast Year [2032] USD 72.55 billion
CAGR (%) 5.90%

A focused orientation to the clinical, operational, and commercial dynamics shaping blood and plasma component management for health systems and industry leaders

The blood and plasma components landscape occupies a central role in modern healthcare delivery, underpinning therapeutic protocols, diagnostic workflows, and biomedical research. This introduction frames the core clinical and commercial contours that influence supply chains and stakeholder decision-making. It synthesizes recent advances in component processing, the evolving regulatory environment, and shifting patterns of clinical demand, establishing a foundation for readers to interpret subsequent analytical chapters.

Clinicians and procurement leaders face a complex interplay of clinical need and supply chain constraints. On one hand, therapeutic reliance on plasma proteins such as immunoglobulins and coagulation factors remains high across diverse indications. On the other hand, operational pressures-ranging from donor recruitment and collection logistics to cold-chain management and distribution channel transformations-require integrated responses across institutions. By framing the primary vectors of change, this introduction prepares leaders to evaluate risk, prioritize resilience measures, and align investment with clinical imperatives.

The section closes by articulating the analytical approach used throughout the report: a focus on product-specific dynamics, application-driven utilization patterns, end-user operational realities, and distribution channel effectiveness. This orientation equips readers to follow the subsequent deep-dive analyses with clarity and to translate insights into tactical and strategic actions that enhance patient care and institutional robustness.

How technological innovation, regulatory evolution, and supply chain diversification are jointly reshaping demand profiles and resilience strategies across the blood and plasma ecosystem

The sector is experiencing transformative shifts that recalibrate how stakeholders manage supply, quality, and commercial strategy. Technological advances in plasma fractionation and pathogen reduction have improved product safety and shelf life, while innovations in subcutaneous delivery formats and recombinant alternatives are reshaping therapeutic use patterns. Concurrently, digitalization of donor engagement and inventory management is optimizing collection throughput and reducing waste, enabling more responsive supply networks. These technology-driven improvements are complemented by changes in clinical practice, where precision medicine and targeted therapeutics are influencing demand composition across product classes.

Policy and regulatory evolution also drives transformation. Regulators are deploying more rigorous pharmacovigilance expectations and novel guidance on plasma-derived products that demand closer lifecycle oversight from manufacturers and distributors. Moreover, geopolitical tensions and trade policy adjustments have increased the emphasis on regional self-reliance and diversified sourcing, prompting firms and health systems to reconsider single-supplier dependencies. As a result, commercial models are shifting toward strategic partnerships, domestic capacity expansion, and flexible distribution agreements that can withstand policy shocks.

Taken together, these shifts create an environment in which agility, technological adoption, and regulatory foresight become critical differentiators. Organizations that invest in integrated supply chain visibility, adopt safer and more efficient processing technologies, and proactively engage with evolving regulatory frameworks will be better positioned to meet clinical demand while maintaining cost-effectiveness and quality standards.

Assessing how recent tariff realignments and trade policy shifts are reconfiguring procurement strategies, regional production decisions, and supply resilience for blood and plasma inputs

Recent tariff measures and trade policy developments have introduced new layers of complexity into procurement and distribution strategies for blood and plasma components. Tariff adjustments affecting imported raw materials, specialized reagents, and finished plasma-derived products have increased cost pressure for suppliers and health systems, compelling procurement teams to reassess sourcing geographies and supplier agreements. In response, many organizations have prioritized supply chain transparency and scenario planning to mitigate exposure to cross-border cost volatility.

Beyond direct cost impacts, tariff shifts influence strategic behaviors among manufacturers and distributors. Some producers have accelerated regionalization of production and established additional processing hubs to circumvent tariff-related frictions and to maintain access to key markets. Distributors, in turn, have diversified inventory holdings and renegotiated contractual terms with health systems to share risk and preserve continuity of care. These adaptations often involve longer-term commercial commitments and investments in local cold-chain infrastructure, which can stabilize supply but may also raise capital intensity.

Clinicians and hospital operations teams feel the downstream effects in procurement cycles and inventory policies. Planning horizons have lengthened as stakeholders incorporate potential tariff disruptions into stocking and substitution decisions, and collaboration across procurement, clinical, and regulatory teams has become essential to maintain treatment pathways. Ultimately, the evolving tariff landscape underscores the need for multi-layered resilience strategies that combine local capacity building, flexible distribution models, and proactive regulatory engagement to safeguard patient access and clinical continuity.

Deep segmentation-driven clarity that links product classes, clinical applications, end-user behaviors, and distribution channels to operational priorities and commercial tactics for market participants

Segmentation analysis reveals nuanced dynamics across product, application, end-user, and distribution channel dimensions, each of which drives distinct operational and commercial implications. Based on product type, the market differentiates between plasma proteins, platelets, red blood cells, and white blood cells. Plasma proteins themselves require a deeper lens: albumin plays a central role in volume and critical care management; coagulation factors must be examined across Factor IX, Factor VIII, and prothrombin complex concentrates due to their specific therapeutic applications and manufacturing considerations; and immunoglobulins are split into intravenous and subcutaneous modalities, each with unique administration and supply requirements.

Based on application, diagnostic, research, and therapeutic uses produce divergent demand rhythms and regulatory expectations. Diagnostic consumption emphasizes consistent availability for laboratory workflows and reagent quality, research demand fluctuates with grant cycles and clinical trial activity, and therapeutic utilization follows clinical practice patterns and treatment protocol adoption. Based on end user, diagnostic laboratories, hospitals, and research institutions impose different procurement constraints and service expectations. Within hospitals, the spectrum includes ambulatory surgical centers, government hospitals, and private hospitals, each exhibiting distinct purchasing power, inventory practices, and clinical pathway integration. Based on distribution channel, hospital pharmacies, online pharmacies, and retail pharmacies vary in their fulfillment models, regulatory compliance requirements, and patient access touchpoints, affecting how products are delivered and managed at the point of care.

These segmentation lenses intersect to create complex value chains. For example, immunoglobulin demand in private hospitals delivered via hospital pharmacies requires different contracting and logistic arrangements than immunoglobulin for research supplied through online pharmacy channels. Recognizing these intersections enables more precise prioritization of investments in cold-chain capacity, formulation innovation, and channel-specific commercial tactics that align product attributes with end-user needs and distribution realities.

How regional regulatory diversity, infrastructure maturity, and distribution architectures across the Americas, Europe Middle East & Africa, and Asia-Pacific shape strategic market entry and operational design

Regional dynamics significantly condition strategic options for manufacturers, distributors, and healthcare providers. The Americas show a concentrated blend of advanced processing infrastructure, well-established donor programs, and mature reimbursement frameworks that favor rapid adoption of technological improvements and scalable distribution networks. In contrast, Europe, Middle East & Africa presents a mosaic of regulatory regimes, heterogeneous healthcare financing arrangements, and varying levels of domestic manufacturing capability, which together demand tailored regulatory strategies and selective investments in regional hub models to ensure supply continuity.

Asia-Pacific demonstrates rapid growth in healthcare infrastructure investment, expansion of domestic plasma collection capacity, and a rising emphasis on localized manufacturing to meet growing clinical demand. Within each region, differences in procurement sophistication, regulatory stringency, and distribution channel maturity influence how organizations design supply strategies and commercial partnerships. For instance, markets with advanced hospital pharmacy networks can deploy centralized inventory optimization tools, whereas regions with diverse retail and online channels may require omnichannel distribution strategies and enhanced cold-chain monitoring.

Taken together, regional insights underscore the importance of differentiated market entry approaches and adaptive operational models. Firms that calibrate their commercial propositions to regional regulatory landscapes, payer mechanisms, and distribution architectures will more effectively balance access, quality, and cost considerations across global footprints.

Profiles of industry players that combine manufacturing excellence, regulatory foresight, and distribution agility to secure clinical trust and operational resilience across product lines

Leading organizations within the sector demonstrate a convergence of capabilities that combine advanced manufacturing, integrated quality management, and strategic distribution partnerships. Companies that invest in modern fractionation and pathogen mitigation technologies secure both regulatory confidence and clinical trust, while those that emphasize supply chain transparency and digital inventory controls reduce waste and improve allocation precision. Strategic alliances between manufacturers and hospital networks facilitate demand forecasting and buffer management, enabling more responsive replenishment and reduced clinical disruption.

Competitive differentiation increasingly arises from portfolio breadth and modality flexibility. Firms offering varied formulations-such as both intravenous and subcutaneous immunoglobulins-and a portfolio that spans albumin and targeted coagulation factors, can better meet heterogeneous clinical needs. Additionally, companies that develop multi-channel distribution models, incorporating hospital pharmacies, online fulfillment, and retail partnerships, create more resilient access pathways for patients and providers. Effective companies also engage regulators proactively, collaborating on post-market surveillance and safety reporting to maintain product integrity and market trust.

Ultimately, the organizations that perform best combine technical excellence in processing with commercial agility and an ability to partner across the ecosystem. Their capabilities in manufacturing, regulatory navigation, and distribution orchestration position them to respond to shifting clinical protocols and supply chain pressures while maintaining patient safety.

Practical and strategic recommendations for executive teams to strengthen manufacturing safety, diversify supply networks, and enhance digital and regulatory capabilities for enduring resilience

Industry leaders should adopt a proactive stance that integrates technological investment, strategic partnerships, and operational resilience measures to navigate current complexities. First, accelerating deployment of advanced processing and pathogen-reduction technologies will improve product safety and reduce wastage, thereby strengthening clinical and regulatory confidence. Concurrently, investing in end-to-end digital visibility-from donor recruitment analytics through inventory and cold-chain monitoring-will enable more accurate demand forecasting and rapid response to supply disruptions.

Second, leaders must cultivate diversified supply strategies that blend regional production capacity, multi-supplier agreements, and flexible distribution arrangements tailored to hospital pharmacies, online fulfillment, and retail channels. These strategies should be coupled with contractual terms that share risk and incentivize service continuity. Third, proactive regulatory engagement is essential: companies and healthcare institutions should invest in dedicated regulatory intelligence and pharmacovigilance capabilities to anticipate policy shifts and to respond efficiently to safety queries.

Finally, close collaboration between manufacturers, clinical leaders, and procurement teams will translate strategic intent into operational reality. Joint scenario planning, shared KPIs for supply reliability, and periodic cross-functional reviews will align incentives and reduce the risk of treatment interruption. By implementing these measures, industry leaders can enhance patient access while managing cost and compliance imperatives.

A transparent and reproducible research approach combining expert interviews, regulatory and clinical literature review, and scenario analysis to ensure actionable and validated insights

The research methodology combines multi-source qualitative analysis, stakeholder interviews, and structured secondary research to build a rigorous and reproducible evidence base. Primary engagement included expert interviews with clinical leaders, procurement officers, supply chain managers, and regulatory specialists to capture real-world operational constraints and strategic priorities. These conversations informed thematic analyses and validated assumptions about product utilization patterns and channel behaviors.

Secondary research involved systematic review of peer-reviewed literature, regulatory guidance documents, and publicly available clinical guidelines to triangulate findings and ensure alignment with current practice standards. The analytic process emphasized cross-validation: insights derived from interviews were compared against documented regulatory developments and clinical practice trends to reduce bias. In addition, scenario analyses were used to explore the implications of supply disruptions, trade policy shifts, and technology adoption, enabling robust recommendations that reflect plausible operational futures.

Throughout the methodology, emphasis was placed on transparency, reproducibility, and practical relevance. The result is a structured framework that links evidence to conclusions and that supports decision-makers in translating insights into targeted actions across procurement, clinical operations, and commercial strategy.

Strategic synthesis of clinical, operational, and commercial implications that underscores the urgency of coordinated modernization and resilience initiatives across the sector

The conclusion synthesizes the report's core implications for clinical, commercial, and operational stakeholders. The blood and plasma components arena is at a strategic inflection point where technological innovation, regulatory change, and supply chain reconfiguration intersect to redefine resilience and access. Organizations that prioritize investment in safer processing technologies, robust digital visibility, and diversified supply networks will be better equipped to absorb shocks and to maintain continuity of care for patients reliant on these critical therapies.

Moreover, the interplay of product segmentation, application-specific demand, and distribution channel dynamics requires coordinated cross-functional strategies. Procurement leaders, clinical directors, and manufacturing executives must align incentives and share real-time information to prevent shortages, optimize inventory, and support evidence-driven substitution where clinically appropriate. Regional strategies should reflect local regulatory regimes and distribution architectures, while commercial approaches must maintain flexibility to accommodate differing end-user needs.

In closing, success in this sector depends on marrying technical excellence with strategic adaptability. Stakeholders that act decisively to modernize operations, engage regulators proactively, and form resilient partnerships will secure both clinical reliability and competitive advantage in a dynamic environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing demand for recombinant albumin alternatives driven by supply constraints in human plasma
  • 5.2. Development of hyperimmunoglobulin therapies targeting emerging infectious diseases to bolster passive immunity
  • 5.3. Expansion of fractionation capacity in Asia Pacific to meet rising demand for immunoglobulin therapies
  • 5.4. Adoption of pathogen reduction technologies in blood processing to enhance transfusion safety standards
  • 5.5. Growing investment in continuous flow plasmapheresis devices to improve donor throughput and efficiency
  • 5.6. Rising corporate consolidation among plasma fractionators reshaping competitive dynamics and pricing
  • 5.7. Shift towards decentralized blood banking models using point-of-care testing to expand rural accessibility
  • 5.8. Integration of artificial intelligence for predictive donor screening and supply chain optimization
  • 5.9. Emergence of recombinant coagulation factors reducing dependency on plasma-derived concentrates
  • 5.10. Implementation of novel viral inactivation methods to address safety concerns in plasma products

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood & Plasma Components Market, by Product Type

  • 8.1. Plasma Proteins
    • 8.1.1. Albumin
    • 8.1.2. Coagulation Factors
      • 8.1.2.1. Factor IX
      • 8.1.2.2. Factor VIII
      • 8.1.2.3. Prothrombin Complex Concentrates
    • 8.1.3. Immunoglobulins
      • 8.1.3.1. Intravenous Immunoglobulin
      • 8.1.3.2. Subcutaneous Immunoglobulin
  • 8.2. Platelets
  • 8.3. Red Blood Cells
  • 8.4. White Blood Cells

9. Blood & Plasma Components Market, by Application

  • 9.1. Diagnostic
  • 9.2. Research
  • 9.3. Therapeutic

10. Blood & Plasma Components Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Hospitals
    • 10.2.1. Ambulatory Surgical Centers
    • 10.2.2. Government Hospitals
    • 10.2.3. Private Hospitals
  • 10.3. Research Institutions

11. Blood & Plasma Components Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Blood & Plasma Components Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Blood & Plasma Components Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Blood & Plasma Components Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. CSL Limited
    • 15.3.2. Grifols, S.A.
    • 15.3.3. Takeda Pharmaceutical Company Limited
    • 15.3.4. Octapharma AG
    • 15.3.5. Biotest AG
    • 15.3.6. KEDRION S.p.A.
    • 15.3.7. Shanghai RAAS Blood Products Co., Ltd
    • 15.3.8. Bio Products Laboratory Limited
    • 15.3.9. LFB S.A.
    • 15.3.10. Sanquin Blood Supply Foundation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BLOOD & PLASMA COMPONENTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BLOOD & PLASMA COMPONENTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BLOOD & PLASMA COMPONENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ALBUMIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ALBUMIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ALBUMIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ALBUMIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ALBUMIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR IX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR IX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR IX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR IX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR IX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR IX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR VIII, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR VIII, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR VIII, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR VIII, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR VIII, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR VIII, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLATELETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLATELETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLATELETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLATELETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLATELETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLATELETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RED BLOOD CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RED BLOOD CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RED BLOOD CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RED BLOOD CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RED BLOOD CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RED BLOOD CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY WHITE BLOOD CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY WHITE BLOOD CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY WHITE BLOOD CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY WHITE BLOOD CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY WHITE BLOOD CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY WHITE BLOOD CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC BLOOD & P